Multispecies-Specific Veterinary (Pet) Antibody Development Service

Creative Biolabs is engineering the future of animal health. Are you currently facing challenges in developing effective and safe antibody therapeutics for multiple companion animal species? Our Multispecies-Specific Veterinary (Pet) Antibody Development Service helps you accelerate pet drug discovery and create broad-spectrum biologics through our advanced antibody engineering platform. We specialize in discovering antibodies against highly conserved epitopes, enabling a single therapeutic candidate to be effective and safe across different species, significantly reducing your development timelines and costs.

Introduction

Our end-to-end service is designed to provide you with therapeutic antibody candidates optimized for veterinary applications. We manage the entire discovery and engineering pipeline, from initial target assessment to delivering a panel of species-specific or cross-reactive antibodies with desirable therapeutic properties. We focus on generating molecules with high affinity, specificity, and manufacturability, tailored to meet the unique physiological demands of companion animals.

Request a Consultation

Workflow

Fig 1. Multispecies-Specific Antibody Development Service Workflow. (Creative Biolabs Original)

Target Analysis & Custom Strategy Design	We begin with in-depth bioinformatic analysis of the target antigen across species to identify conserved epitopes suitable for cross-reactive antibody generation. Based on your therapeutic goals, we tailor a discovery approach using technologies like phage display or single B-cell cloning.
Antibody Discovery & High-Throughput Screening	Leveraging our optimized antibody libraries and biopanning platforms, we perform iterative screening to isolate high-affinity antibody fragments (e.g., Fabs, scFvs) with strong binding specificity to your target antigen.
Hit Characterization & Cross-Species Validation	Top hits are expressed and characterized using binding affinity assays and cross-reactivity tests against antigen orthologs from multiple species. The best-performing candidates are advanced for further development.
Antibody Engineering & Format Optimization	Selected leads are reformatted into full-length IgG with species-matched Fc regions (e.g., canine or feline). Advanced engineering, such as affinity maturation, stability optimization, or Fc modification, is applied to enhance therapeutic functionality and in vivo performance.
Functional Validation & Characterization	Engineered antibodies undergo rigorous biological testing in relevant cell-based assays to evaluate their functional activity, ensuring therapeutic relevance across species.
Data Analysis & Report Delivery	A detailed report is provided, including sequence information, affinity data, specificity profiles, and results from all in vitro functional assays. We also offer downstream services such as in vivo evaluation and antibody production to support further development.

Why Choose Us?

True Multispecies Expertise
Our proprietary target analysis pipeline identifies highly conserved epitopes, enabling the creation of single antibody candidates that are effective in both dogs and cats, drastically simplifying downstream development and regulatory pathways.
Advanced Engineering for Safety and Efficacy
We specialize in caninization and felinization, modifying antibodies to minimize immunogenicity risks in target animals. By using species-specific Fc domains, we ensure optimal half-life and effector function, leading to safer and more effective treatments.
High-Quality, Characterized Candidates
We provide fully characterized lead molecules with comprehensive data packages covering affinity, specificity, cross-reactivity, and in vitro biological function, ensuring you receive candidates ready for the next phase of preclinical evaluation.

FAQs

1. What is the main advantage of developing a cross-reactive antibody instead of two separate ones for dogs and cats?

Developing a single antibody that is effective in both species can significantly reduce overall development costs and timelines. It simplifies manufacturing, quality control, and regulatory submissions, allowing you to bring a much-needed therapy to market for multiple species more efficiently. We can discuss if this strategy is right for your specific target.

2. How do you ensure the antibodies you develop won't be rejected by the animal's immune system?

We use a process called caninization or felinization, where we engineer the antibody sequence to be as close as possible to the animal's own antibodies. This involves grafting the binding loops (CDRs) onto a species-appropriate framework and using a canine or feline constant region (Fc), which drastically reduces the risk of an anti-drug antibody (ADA) response

Related Services

To fully support your veterinary therapeutic pipeline, Creative Biolabs offers a range of specialized services that complement our multispecies discovery platform.

Caninization Service

Adapt your existing lead antibody for optimal safety and function in canine species.

Felinization Service

Engineer antibodies to minimize immunogenicity and maximize efficacy in feline species.

Pet Antibody Characterization

Comprehensive biophysical and functional analysis to fully profile your therapeutic candidate.

Pet Therapeutic Antibody Evaluation

In vitro and in vivo assay development to validate the mechanism of action of your veterinary antibody.

Partner with Creative Biolabs

Creative Biolabs is committed to advancing animal health through cutting-edge science. Our multispecies-specific antibody development service provides a direct path to creating innovative, safe, and effective biologics for the companion animals that need them most.

Ready to discuss your project? Our team of experts is available to answer your questions and design a custom service plan tailored to your research goals. Contact our team to discover how we can help with your antibody discovery project.

Contact Our Team

Services